None listed
Conditions
Brief summary
Hyperuricemia and metabolic acidosis have emerged as important risk factors for progression of kidney disease. In this study, we aimed to investigate the effects of allopurinol on metabolic acidosis and endothelial functions in hyperuricemic stage 2-4 chronic kidney disease (CKD) patients. Thirty patients with stage 2-4 CKD and serum uric acid levels over 5.5 mg/dL were included in the study group. They were prescribed 300 mg/day per oral allopurinol treatment for three months. Age and gender matched CKD patients (n=30) with similar clinical characteristics were taken as the control group and they were not given allopurinol treatment. Endothelial functions were measured via flow mediated dilatation (FMD) over forearm. pH and HCO3 levels in venous blood, Cr clearance and proteinuria levels were calculated in all patients at baseline and during the third month. Serum uric acid levels significantly decreased in the study group. Cr clearance, serum bicarbonate levels and FMD values have increased significantly in allopurinol group. There were not any significant changes except FMD values in the control group. FMD variations within two groups were clearly significant in repeated ANOVA general linear model. In conclusion, we assume that decreasing uric acid levels with allopurinol treatment seems to be helpful in order to restore endothelial functions, prevent metabolic acidosis and slow down the progression of CKD.
Interventions
Hyperuricemia and metabolic acidosis have emerged as important risk factors for progression of kidney disease. In this study, we aimed to investigate the effects of allopurinol on metabolic acidosis and endothelial functions in hyperuricemic stage 2-4 chronic kidney disease (CKD) patients. Thirty patients with stage 2-4 CKD and serum uric acid levels over 5.5 mg/dL were included in the study group. They were prescribed 300 mg/day per oral allopurinol treatment for three months. In order to monit
Hyperuricemia and metabolic acidosis have emerged as important risk factors for progression of kidney disease. In this study, we aimed to investigate the effects of allopurinol on metabolic acidosis and endothelial functions in hyperuricemic stage 2-4 chronic kidney disease (CKD) patients. Thirty patients with stage 2-4 CKD and serum uric acid levels over 5.5 mg/dL were included in the study group. They were prescribed 300 mg/day per oral allopurinol treatment for three months. In order to monitor adherence to the intervention, we have counted allopurinol tablets in the clinical visits. Age and gender matched CKD patients (n=30) with similar clinical characteristics were taken as the control group and they were not given allopurinol treatment. Endothelial functions were measured via flow mediated dilatation over forearm. pH and HCO3 levels in venous blood, Cr clearance and proteinuria levels from 24 hour urine collection were calculated in all patients at baseline and during the third month.
Sponsors
Dilara Bayram
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
The inclusion criteria were as follows; being a CKD patient at stage 2-4, age between 18 and 80 years old, having serum uric acid levels over 5.5 mg/dl and giving written informed consent to enter this study.
Exclusion criteria
The exclusion criteria were: being on renal replacement therapy, hyperuricemia due to malignancy, having peripheral arterial disease, gouty arthritis, a history of allopurinol intolerance, being already on allopurinol treatment, having active infections or inflammatory diseases.
Outcome results
None listed